Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: A prospective clinical study (data updated)

被引：1

作者：

Yang, M. ^{[1
]}

Gao, J. ^{[1
]}

Liu, X. ^{[1
]}

Lu, H. ^{[1
]}

机构：

[1] Shanxi Canc Hosp, Digest Dept Oncol, Taiyuan, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1934

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1428P

引用

页码：S903 / S903

页数：1

共 50 条

[31] Clinical impact of oral intake on second-line treatment of advanced gastric cancer.
Ogata, Takatsugu
Narita, Yukiya
Kumanishi, Ryosuke
Nakazawa, Taiko
Matsubara, Yuki
Nozawa, Kazuki
Kato, Kyoko
Honda, Kazunori
Masuishi, Toshiki
Bando, Hideaki
Kadowaki, Shigenori
Ando, Masashi
Tajika, Masahiro
Muro, Kei
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[32] Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
Cotes Sanchis, Almudena
Gallego, Javier
Hernandez, Raquel
Arrazubi, Virginia
Custodio, Ana
Maria Cano, Juana
Aguado, Gema
Macias, Ismael
Lopez, Carlos
Lopez, Flora
Visa, Laura
Garrido, Marcelo
Martinez Lago, Nieves
Fernandez Montes, Ana
Luisa Limon, Maria
Azkarate, Aitor
Pimentel, Paola
Reguera, Pablo
Ramchandani, Avinash
Diego Cacho, Juan
Martin Carnicero, Alfonso
Granja, Monica
Martin Richard, Marta
Hernandez Perez, Carolina
Hurtado, Alicia
Serra, Olbia
Buxo, Elvira
Vidal Tocino, Rosario
Jimenez-Fonseca, Paula
Carmona-Bayonas, Alberto
PLOS ONE, 2020, 15 (07):
[33] Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma
Kunisaki, C
Imada, T
Yamada, R
Hatori, S
Ono, H
Otsuka, Y
Matsuda, G
Nomura, M
Akiyama, H
Kubo, A
Shimada, H
ANTICANCER RESEARCH, 2005, 25 (04) : 2973 - 2977
[34] Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel - Cisplatin
Polyzos, Aristides
Tsavaris, Nikolas
Kosmas, Christos
Polyzos, Kostas
Giannopoulos, Athanasios
Felekouras, Evangelos
Nikiteas, Nikolas
Kouraklis, Gregory
Griniatsos, John
Safioleas, Michael
Stamatakos, Michael
Pikoulis, Emmanuel
Papachristodoulou, Antonios
Gogas, Helen
ANTICANCER RESEARCH, 2006, 26 (5B) : 3749 - 3753
[35] Second-line chemotherapy with combined docetaxel and cisplatin for patients with far advanced gastric carcinoma.
Kunisaki, C
Akiyama, H
Otsuka, Y
Matsuda, G
Nomura, M
Hatori, S
Imada, T
Togo, S
Ike, H
Shimada, H
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 366S - 366S
[36] Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
Chao Jing
Junyun Wang
Mingyue Zhu
Zhigang Bai
Baoyi Zhao
Jun Zhang
Jie Yin
Xiaobao Yang
Zongzhi Liu
Zhongtao Zhang
Wei Deng
Cancer Immunology, Immunotherapy, 2022, 71 : 2597 - 2608
[37] Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
Jing, Chao
Wang, Junyun
Zhu, Mingyue
Bai, Zhigang
Zhao, Baoyi
Zhang, Jun
Yin, Jie
Yang, Xiaobao
Liu, Zongzhi
Zhang, Zhongtao
Deng, Wei
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (11) : 2597 - 2608
[38] Efficacy and adverse reactions of apatinib as second-line or later-line treatment in advanced lung cancer
Tao Ren
Yan Wu
Oncology and Translational Medicine, 2021, 7 (04) : 160 - 164
[39] Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy
Ruan, Hanguang
Dong, Junlin
Zhou, Xueliang
Xiong, Juan
Wang, Hua
Zhong, Xiaoming
Cao, Xiaolong
ONCOTARGET, 2017, 8 (61) : 104552 - 104559
[40] Docetaxel in the first- and second-line therapy of gastric cancer
Vanhoefer, U
ONKOLOGIE, 2000, 23 : 40 - 42

← 1 2 3 4 5 →